

A Conversation with the Investigators: Hormonal Therapy for Prostate Cancer
(Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following agents is more commonly associated with cardiac toxicity?
 - Abiraterone
 - Apalutamide
 - Enzalutamide
- Which of the following statements is true regarding the results from the Phase III HERO trial of relugolix, an oral gonadotropin-releasing hormone antagonist, compared to standard leuprolide for patients with advanced prostate cancer?
 - Relugolix achieved a sustained suppression of testosterone levels that was inferior to that with leuprolide
 - Relugolix achieved a sustained suppression of testosterone levels that was equivalent to that with leuprolide
 - Relugolix achieved a sustained suppression of testosterone levels that was superior to that with leuprolide
- Which of the following populations of patients with prostate cancer is being investigated in the ongoing Phase III ARASENS trial of androgen-deprivation therapy (ADT) with or without darolutamide for patients who are candidates for ADT and docetaxel?
 - Patients with nonmetastatic castration-resistant prostate cancer (CRPC)
 - Patients with metastatic CRPC
 - Patients with nonmetastatic hormone-sensitive prostate cancer (HSPC)
 - Patients with metastatic HSPC
- The PROSPER trial evaluated the addition of enzalutamide to ADT for men with nonmetastatic CRPC and rapidly increasing prostate-specific antigen levels. Which of the following survival outcomes was reported in favor of the enzalutamide arm?
 - A significant improvement in metastasis-free survival (MFS) only
 - A significant improvement in overall survival (OS) only
 - A significant improvement in both MFS and OS
 - No significant improvement in MFS or OS